EyePoint Pharmaceuticals Inc - ESG Rating & Company Profile powered by AI
Other corporations in the scoring industry group for EyePoint Pharmaceuticals Inc are displayedin the table. Jump to the end of the webpage for potential risks for EyePoint Pharmaceuticals Inc based on industry, geography and size. This webpage includes a Q&A table for EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 1.3; made up of an environmental score of 0.0, social score of 0.0 and governance score of 4.0.
1.3
Low ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
... | ... | ... | |
1747 | Sinphar Pharmaceutical Co Ltd | 1.4 | Low |
1747 | WooGene B&G Co Ltd | 1.4 | Low |
1755 | EyePoint Pharmaceuticals Inc | 1.3 | Low |
1755 | Cheng Du Sheng Nuo Biotec Co Ltd | 1.3 | Low |
1755 | ALX Oncology Holdings Inc | 1.3 | Low |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does EyePoint Pharmaceuticals Inc have an accelerator or VC vehicle to help deliver innovation?
Does EyePoint Pharmaceuticals Inc disclose current and historical energy intensity?
Does EyePoint Pharmaceuticals Inc report the average age of the workforce?
Does EyePoint Pharmaceuticals Inc reference operational or capital allocation in relation to climate change?
Does EyePoint Pharmaceuticals Inc disclose its ethnicity pay gap?
Does EyePoint Pharmaceuticals Inc disclose cybersecurity risks?
Does EyePoint Pharmaceuticals Inc offer flexible work?
Does EyePoint Pharmaceuticals Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does EyePoint Pharmaceuticals Inc disclose the number of employees in R&D functions?
Does EyePoint Pharmaceuticals Inc conduct supply chain audits?
Does EyePoint Pharmaceuticals Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does EyePoint Pharmaceuticals Inc conduct 360 degree staff reviews?
Does EyePoint Pharmaceuticals Inc disclose the individual responsible for D&I?
Does EyePoint Pharmaceuticals Inc disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does EyePoint Pharmaceuticals Inc disclose current and / or historical scope 2 emissions?
Does EyePoint Pharmaceuticals Inc disclose water use targets?
Does EyePoint Pharmaceuticals Inc have careers partnerships with academic institutions?
Did EyePoint Pharmaceuticals Inc have a product recall in the last two years?
Does EyePoint Pharmaceuticals Inc disclose incidents of discrimination?
Does EyePoint Pharmaceuticals Inc allow for Work Councils/Collective Agreements to be formed?
Has EyePoint Pharmaceuticals Inc issued a profit warning in the past 24 months?
Does EyePoint Pharmaceuticals Inc disclose parental leave metrics?
Does EyePoint Pharmaceuticals Inc disclose climate scenario or pathway analysis?
Does EyePoint Pharmaceuticals Inc disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does EyePoint Pharmaceuticals Inc disclose the pay ratio of women to men?
Does EyePoint Pharmaceuticals Inc support suppliers with sustainability related research and development?
Does EyePoint Pharmaceuticals Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does EyePoint Pharmaceuticals Inc reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is EyePoint Pharmaceuticals Inc involved in embryonic stem cell research?
Does EyePoint Pharmaceuticals Inc disclose GHG and Air Emissions intensity?
Does EyePoint Pharmaceuticals Inc disclose its waste policy?
Does EyePoint Pharmaceuticals Inc report according to TCFD requirements?
Does EyePoint Pharmaceuticals Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does EyePoint Pharmaceuticals Inc disclose energy use targets?
Does EyePoint Pharmaceuticals Inc disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does EyePoint Pharmaceuticals Inc have a policy relating to cyber security?
Have a different question?
Potential Risks for EyePoint Pharmaceuticals Inc
These potential risks are based on the size, segment and geographies of the company.
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.